222 related articles for article (PubMed ID: 15550488)
1. Antileukemic activity of rapamycin in acute myeloid leukemia.
Récher C; Beyne-Rauzy O; Demur C; Chicanne G; Dos Santos C; Mas VM; Benzaquen D; Laurent G; Huguet F; Payrastre B
Blood; 2005 Mar; 105(6):2527-34. PubMed ID: 15550488
[TBL] [Abstract][Full Text] [Related]
2. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.
Tamburini J; Green AS; Bardet V; Chapuis N; Park S; Willems L; Uzunov M; Ifrah N; Dreyfus F; Lacombe C; Mayeux P; Bouscary D
Blood; 2009 Aug; 114(8):1618-27. PubMed ID: 19458359
[TBL] [Abstract][Full Text] [Related]
3. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
Janus A; Linke A; Cebula B; Robak T; Smolewski P
Anticancer Drugs; 2009 Sep; 20(8):693-701. PubMed ID: 19584709
[TBL] [Abstract][Full Text] [Related]
6. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation.
Green AS; Chapuis N; Maciel TT; Willems L; Lambert M; Arnoult C; Boyer O; Bardet V; Park S; Foretz M; Viollet B; Ifrah N; Dreyfus F; Hermine O; Moura IC; Lacombe C; Mayeux P; Bouscary D; Tamburini J
Blood; 2010 Nov; 116(20):4262-73. PubMed ID: 20668229
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
[TBL] [Abstract][Full Text] [Related]
8. Determinants of rapamycin sensitivity in breast cancer cells.
Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
[TBL] [Abstract][Full Text] [Related]
9. [Synergistic effect of rapamycin (RPM) and PD98059 on cell cycle and mTOR signal transduction in human colorectal cancer cells].
Zhang YJ; Fang JY; Sun DF; Zhao SL; Shen GF; Zheng Q; Zhu HY
Zhonghua Zhong Liu Za Zhi; 2007 Dec; 29(12):889-93. PubMed ID: 18478925
[TBL] [Abstract][Full Text] [Related]
10. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.
Dutton A; Reynolds GM; Dawson CW; Young LS; Murray PG
J Pathol; 2005 Mar; 205(4):498-506. PubMed ID: 15714459
[TBL] [Abstract][Full Text] [Related]
11. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
Bishop JD; Nien WL; Dauphinee SM; Too CK
J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.
Zeng Z; Sarbassov dos D; Samudio IJ; Yee KW; Munsell MF; Ellen Jackson C; Giles FJ; Sabatini DM; Andreeff M; Konopleva M
Blood; 2007 Apr; 109(8):3509-12. PubMed ID: 17179228
[TBL] [Abstract][Full Text] [Related]
13. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
14. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Mita MM; Mita A; Rowinsky EK
Cancer Biol Ther; 2003; 2(4 Suppl 1):S169-77. PubMed ID: 14508096
[TBL] [Abstract][Full Text] [Related]
15. A functional link between polo-like kinase 1 and the mammalian target-of-rapamycin pathway?
Renner AG; Créancier L; Dos Santos C; Fialin C; Recher C; Bailly C; Kruczynski A; Payrastre B; Manenti S
Cell Cycle; 2010 May; 9(9):1690-6. PubMed ID: 20404504
[TBL] [Abstract][Full Text] [Related]
16. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways.
Liu L; Li F; Cardelli JA; Martin KA; Blenis J; Huang S
Oncogene; 2006 Nov; 25(53):7029-40. PubMed ID: 16715128
[TBL] [Abstract][Full Text] [Related]
18. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
19. The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin.
McMahon LP; Choi KM; Lin TA; Abraham RT; Lawrence JC
Mol Cell Biol; 2002 Nov; 22(21):7428-38. PubMed ID: 12370290
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL).
Nemes K; Sebestyén A; Márk A; Hajdu M; Kenessey I; Sticz T; Nagy E; Barna G; Váradi Z; Kovács G; Kopper L; Csóka M
PLoS One; 2013; 8(4):e59335. PubMed ID: 23573198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
